Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 69.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,114 shares of the medical equipment provider's stock after selling 98,449 shares during the quarter. Schroder Investment Management Group owned 0.06% of Lantheus worth $3,946,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. HighTower Advisors LLC purchased a new position in Lantheus in the third quarter valued at approximately $607,000. Castleark Management LLC increased its stake in Lantheus by 47.4% in the third quarter. Castleark Management LLC now owns 83,640 shares of the medical equipment provider's stock valued at $9,179,000 after purchasing an additional 26,890 shares during the last quarter. Orion Portfolio Solutions LLC increased its stake in Lantheus by 17.2% in the third quarter. Orion Portfolio Solutions LLC now owns 10,291 shares of the medical equipment provider's stock valued at $1,129,000 after purchasing an additional 1,508 shares during the last quarter. MML Investors Services LLC increased its stake in Lantheus by 24.6% in the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider's stock valued at $476,000 after purchasing an additional 857 shares during the last quarter. Finally, Groupama Asset Managment purchased a new position in Lantheus in the third quarter valued at approximately $439,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. Finally, JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Trading Down 2.5 %

Shares of NASDAQ:LNTH traded down $2.55 during midday trading on Thursday, hitting $97.61. 47,246 shares of the stock were exchanged, compared to its average volume of 948,732. The stock has a market cap of $6.68 billion, a P/E ratio of 16.24 and a beta of 0.20. Lantheus Holdings, Inc. has a twelve month low of $58.46 and a twelve month high of $126.89. The company has a 50 day moving average price of $93.62 and a 200-day moving average price of $95.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.